Business Context and Reporting Period
NanoViricides, Inc., a Nevada corporation, filed this Form 8-K on May 12, 2010, to report the entry into a Material Definitive Agreement. The filing details a securities offering executed on May 11, 2010, involving the sale of Series B Convertible Preferred Stock to Seaside 88, LP.
Key Financial Metrics
- Gross Proceeds: $5,000,000 raised from the sale of 500,000 shares of Series B Convertible Preferred Stock.
- Purchase Price: $10.00 per share of Series B Preferred Stock.
- Estimated Offering Expenses: Approximately $490,000, including placement agent and attorney fees.
- Placement Agent Fee: 8% of the gross purchase price paid to Midtown Partners & Co., LLC.
- Initial Conversion Price: $1.87893 per share of Common Stock.
- Debt and Liquidity: The filing does not provide specific data on existing debt, cash flow, or overall liquidity positions outside of the proceeds from this transaction.
Material Changes and Transaction Terms
The primary material change is the capital raise and the associated equity structure. Key terms include:
- Conversion Mechanics: 60,000 shares of Series B Preferred Stock convert automatically into Common Stock at closing and every 14 days thereafter.
- Conversion Formula: The conversion factor is based on the Purchase Price divided by the lower of (i) 85% of the 10-day VWAP or (ii) 88% of the prior day's VWAP.
- Price Floor: Conversions will not occur if the 20-day VWAP is below $0.20; unconverted shares carry over to the next date.
- Option to Purchase: Seaside 88, LP has the right to purchase an additional 500,000 shares of Series B Preferred Stock within six months of the final conversion date under the same terms.
Outlook, Risks, and Management Commentary
Management highlighted several risks associated with the offering in the forward-looking statements:
- Dilution: Substantial dilution to current stockholders is expected due to the purchase price discount offered to Seaside.
- Market Overhang: Potential market overhang may develop from the resale of Common Stock by Seaside upon conversion.
- Closing Conditions: Risks regarding the Company's ability to satisfy closing conditions on a timely basis.
- Regulatory Status: The offering was made pursuant to a shelf registration statement on Form S-3 declared effective on April 29, 2010.
Investor Verification Checklist
- Verify the exact number of shares converted in subsequent 14-day intervals and the resulting dilution impact.
- Confirm the utilization of the $5,000,000 gross proceeds against the Company's stated capital needs.
- Monitor the 20-day VWAP to determine if the $0.20 "Floor" prevents future conversions.
- Assess whether Seaside 88, LP exercises the option to purchase the additional 500,000 shares.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for covenants and indemnification details.